Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment

Trial Profile

Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2010

At a glance

  • Drugs Lamivudine/abacavir (Primary) ; Efavirenz; Lopinavir/ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms LAKE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2010 Results published in Antiviral Research.
    • 04 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top